Business Model & Revenue
The Oncology Institute is one of the largest value-based community oncology groups in the United States. The company operates a differentiated model combining fee-for-service oncology care with capitated (value-based) contracts where TOI takes responsibility for total cost of care in exchange for fixed per-member payments.
Revenue Streams:
- Patient Services — $229.0M (45.5% of 2025 revenue): Traditional fee-for-service oncology care, infusion services, clinical visits
- Specialty Pharmacy — $269.2M (53.5%): In-house pharmacy dispensing oncology drugs, capturing spread on drug costs
- Clinical Trials & Other — $4.6M (1%): Research partnerships and ancillary services
Value-Based/Capitated Model:
- Capitated contracts pay fixed per-member-per-month (PMPM) fees for oncology benefit management
- TOI manages total cost of care through evidence-based clinical pathways
- Higher margins than fee-for-service due to risk-sharing and cost control
- 9 new capitated contracts in 2025 added ≈260,000 lives
Unit Economics:
- Gross margin: 15.2% (2025), expanding toward 16%+ in 2026
- Specialty pharmacy drives volume; capitation drives margin
Financial Highlights
Full-Year 2025 Results
| Metric | 2025 | 2024 | YoY Change |
|---|---|---|---|
| Revenue | $502.7M | $393.4M | +27.8% |
| Gross Profit | $76.4M | $54.0M | +41.6% |
| Gross Margin | 15.2% | 13.7% | +150 bps |
| Net Loss | ($60.6M) | ($64.7M) | Improved |
| Adjusted EBITDA | ($12.4M) | ($35.7M) | +$23.3M |
Quarterly Progression
| Quarter | Revenue | Net Income | Adj. EBITDA | Gross Margin |
|---|---|---|---|---|
| Q1 2025 | $107.8M | ($17.2M) | ($5.2M) | 13.1% |
| Q2 2025 | $120.4M | ($16.8M) | ($3.8M) | 14.2% |
| Q3 2025 | $132.5M | ($19.1M) | ($1.6M) | 14.8% |
| Q4 2025 | $142.0M | ($7.5M) | $0.1M | 16.0% |
Balance Sheet Snapshot
| Item | Dec 2025 | Dec 2024 |
|---|---|---|
| Cash | $33.6M | $49.7M |
| Long-term Debt | $77.4M | $93.1M |
| Stockholders' Equity | ($15.7M) | $3.6M |
| Shares Outstanding | 98.9M | 75.7M |
2026 Guidance:
- Revenue: $630-650M (+25-29% YoY)
- Gross Profit: $97-107M (+27-40% YoY)
- Adjusted EBITDA: $0-9M (breakeven to positive)
- Capitated Revenue: ≈$150M
Competitive Landscape
TOI operates in the fragmented oncology services market, competing with both large national players and regional community oncology practices. The value-based care niche has fewer direct competitors.
Key Competitors:
- US Oncology Network (McKesson): Largest network of community oncologists; ≈1,400 physicians; scale advantage but franchise model limits control
- OneOncology: PE-backed platform; ≈1,000 physicians; aggressive growth through acquisitions
- GenesisCare: Global oncology provider; US presence through acquisitions; filed Chapter 11 in 2023, restructured
- Regional Health Systems: Hospital-employed oncologists; captive referral networks but higher cost structures
- Memorial Sloan Kettering / MD Anderson: Academic centers; premium pricing, limited geographic reach
Moats:
- Capitated Contract Portfolio — ≈$150M 2026 capitated revenue with Elevance, Humana, CarePlus; hard to replicate
- Clinical Pathways — Evidence-based protocols reduce variation and cost; ≈15 years of data
- Scale in Community Setting — 146 clinics, 300+ clinicians; local presence with national infrastructure
- Payer Relationships — Deep partnerships with major Medicare Advantage plans in key states
Catalysts
-
Continued Elevance Florida expansion in 2026 — could more than double current partnership
-
Q1 2026 earnings — expected to show progress toward full-year EBITDA profitability
-
New capitated contract wins — 9 in 2025; additional announcements likely
-
Debt reduction — $15.7M principal paid in 2025; continued deleveraging improves balance sheet
-
Potential for positive GAAP net income in late 2026 or 2027
Key Risks
- Seasonality impacts — Q1 typically weakest due to deductible resets and drug pricing lags
- Payer concentration risk — Elevance partnership represents significant capitated revenue
- Negative book value — stockholders' equity deficit of $15.7M limits financial flexibility
- Regulatory risk — Medicare/Medicaid reimbursement changes could pressure margins
- Execution risk — guidance assumes continued capitated contract wins and margin expansion
Our Thesis
TOI is proving that value-based oncology care can be both growthy and profitable. The Q4 2025 inflection—first positive adjusted EBITDA quarter—validates the model after years of investment. Revenue grew 28% in 2025 while adjusted EBITDA improved by $23M year-over-year, driven by capitated contract expansion and operational leverage. The company now serves 2.0 million lives under value-based contracts across 146 clinics in 17 markets.
Valuation at $258M market cap (≈0.4x 2026 revenue guidance) undervalues the operational turnaround. Applying a conservative 8x multiple to the midpoint of 2026 adjusted EBITDA guidance ($4.5M) plus growth premium yields $5.00+ fair value. The capitated revenue ramp—from essentially zero to ≈$150M in 2026—represents high-margin, recurring revenue that should drive multiple expansion as profitability is demonstrated.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.